Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity ... and other organs.

A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio and pipeline in haematology, including from Alexion, its rare disease group, with data ...

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society of Hematology (ASH) Annual Meeting ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered ...

Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. ALXN-1840 has advanced through a Phase 3 clinical trial ...

His company, Wilmette-based Monopar Therapeutics, announced yesterday it has entered a licensing deal with Alexion and its parent, AstraZeneca, to further develop ALXN-1840, or bis-choline ...

Monopar Therapeutics (NASDAQ:MNPR) rose around 20% ahead of trading on Thursday after it announced an agreement with Alexion, ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with ...

Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile ...